Ipsen at ASCO GI 2018

We are excited to be participating in the 2018 ASCO GI congress in San Francisco from the 18th until the 20th of January.

Discover all activities Ipsen is organizing and data we are sharing at this year’s congress.

Want to know more about the activities Ipsen is organizing and data we are sharing at this year’s ASCI GI?
Visit our new website www.ipsenevents.com* to learn more!


“Ipsen has a strong presence in oncology at ASCO-GI 2018 with 13 posters dealing with clinical outcomes in pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors and carcinoid syndrome. We and Exelixis, our partner, are excited to announce that the results of the pivotal Phase 3 CELESTIAL Trial of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma will be shared for the first time with the medical community as a late breaking presentation, on January 19th,” said Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen.

Ipsen will be organizing an investor briefing with EXELIXIS at ASCO GI 2018 on January 19, 2018 at 6:30 p.m. PST from the InterContinental San Francisco’s Grand Ballroom A (888 Howard St., San Francisco).

The event will also be webcast live.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Alternatively, please call +1 (855)-793-2457 (domestic) or +1 (631)-485-4921 (international) and provide the conference call passcode 2478857 to join by phone.

For further other details or information, click on

*The website is only for HCP’s and journalists.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021